Missouri Bill to Study Medical Use of MDMA, Psilocybin and Ketamine Passes Second House Committee

Two legislative committees in Missouri have voted “Yes” on a measure that would require a study on the efficacy of using alternative medicines and therapies including, but not limited to MDMA psilocybin, and ketamine.

(Getty Images)

Missouri House Bill 1154 was passed on March 7 by the Veterans Committee in a unanimous vote (11 to 0), and on Monday it was given approval by the Administrative Oversight Committee. The vote Monday was also unanimous, 10 to 0.

Filed by Representative Dan Houx, this bill “requires the Department of Health and Senior Services, in
collaboration with a Missouri university hospital and medical center operated by the Department of Veterans Affairs in Missouri, to conduct a study on the efficacy of using alternative medicines and therapies, including, but not limited to, the use of MDMA, psilocybin, and ketamine for the treatment of patients suffering from post-traumatic stress disorder, treatment-resistant depression, substance abuse disorders, or who require end-of-life care.”

The bill specifies that such study must include a clinical trial of psilocybin, as well as a literature review and the submission of various reports, and states that “No person participating in the clinical trial shall be subjected to criminal or civil liability or sanction for the participation in the clinical trial, except in cases of gross negligence or willful misconduct.”

The Department of Health and Senior Services shall prepare and submit to the Governor, Lieutenant Governor and the General Assembly:

(1) Quarterly reports on the progress of the study; and

(2) A written report, submitted one year after the study begins, containing the results of the study and any recommendations for legislation.

House Bill 1154 clarifies that the Department shall maintain the confidentiality of any personally
identifiable protected information collected during the clinical trial.

Thank you for reading The Marijuana Herald! You can sign up for our newsletter at the form below, and you can find more news stories by clicking here.